BioAge Labs (BIOA) Accounts Payables (2023 - 2026)

BioAge Labs has disclosed Accounts Payables across 4 years of filings, most recently posting $3.1 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $3.1 million, down 23.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 million (down 23.14% YoY), and the FY2025 annual result was $2.7 million, up 33.97% from the prior year.
• Accounts Payables came in at $3.1 million for Q1 2026 at BioAge Labs, up from $2.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.0 million in Q3 2025 to a low of $1.3 million in Q2 2025.
• The 4-year median for Accounts Payables is $2.4 million (2024), against an average of $2.8 million.
• Across the five-year window, Accounts Payables jumped 139.18% in 2025 and slipped 23.14% in 2026, its largest moves.
• BioAge Labs' Accounts Payables stood at $1.9 million in 2023, then advanced by 6.97% to $2.0 million in 2024, then soared by 33.97% to $2.7 million in 2025, then increased by 14.66% to $3.1 million in 2026.
• The last three Accounts Payables figures came in at $3.1 million (Q1 2026), $2.7 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.